This white paper examines Belgium’s rapidly expanding anti-obesity medication market, where treated patients tripled between 2022 and 2025 despite no public reimbursement. Nearly half of Belgians are overweight and 18% live with obesity, driving demand as general practitioners increasingly initiate treatment. Women account for about 70% of users, while pharmacists remain underused despite frequent patient contact. Persistence is a major challenge, with most patients stopping treatment within six months because of cost, side effects, inconsistent dosing, and unmet expectations. The paper recommends stronger GP engagement, pharmacist activation, structured support during the first 8–12 weeks, realistic goal setting, and patient-specific communication to improve adherence, outcomes, and susta

Join for free to read